Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 1, 1998, Pages 8-17

  Adedoyin, Adedayo ^b   Arns, Patricia A ^b   Richards, W O ^b   Wilkinson, Grant R ^b   Branch, Robert A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; MEPHENYTOIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER DISEASE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PLASMA CLEARANCE; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; FEMALE; HUMANS; LIVER DISEASES; MALE; MEPHENYTOIN; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; STEREOISOMERISM; SYMPATHOLYTICS;

EID: 0031847721     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90017-0     Document Type: Article

References (52)

1. Adedoyin A, Branch RA. Pharmacokinetics. In: Zakim D, Boyer TD, editors. Hepatology: a textbook of liver disease. Philadelphia: WB Saunders; 1996. p. 307-22.
2. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease [review]. Clin Pharmacokinet 1991;21:42-69.
3. Brouwer KLR, Dukes GE, Powell JR. Influence of liver function on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Vancouver (WA): Applied Therapeutics; 1992. p. 6,1-6,59.
4. Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988;15:396-420.
5. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989;40:439-74.
6. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
7. Juchau MR. Substrate specificities and functions of the P450 cytochromes. Life Sci 1990;47:2385-94.
8. Gonzalez FJ. Human cytochrome P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-52.
9. Homeida M, Roberts CJC, Halliwell M, Read AE, Branch RA. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease. Gut 1979;20:596-601.
10. Schellens JHM, Janssens AR, van der Wart JHF, van der Velde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a cocktail approach. Eur J Clin Invest 1989;19:472-9.
11. Wensing G, Ohnhaus EE, Hoensch HP. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease. Clin Pharmacol Ther 1990;47:698-705.
12. Birnie GG, Thompson GG, Cooke A, Brodie MJ. Antipyrine and indocyanine green kinetics in the prediction of the natural history of liver disease. Br J Clin Pharmacol 1987;23:615P-6P.
13. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973;14:569-73.
14. Farrell GC, Cooksley WGE, Hart P, Powell LW. Drug metabolism in liver disease: identification of patients with impaired hepatic drug metabolism. Gastroenterology 1978;75:580-8.
15. Sotaniemi EA, Pelkonen RO, Puuka M. Measurement of hepatic drug-metabolizing enzyme activity in man: comparison of three different assays. Eur J Clin Pharmacol 1980;17:267-74.
16. McPherson GAD, Benjamin IS, Boobis AR, Brodie MJ, Hampden C, Blumgart LH. Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice. Gut 1982;23:734-8.
17. Denaro CP, Wilson M, Jacob P III, Benowitz NL. The effect of liver disease on urine caffeine metabolite ratios. Clin Pharmacol Ther 1996;59:624-35.
18. Piafsky KM, Sitar DS, Tangno RE, Ogilvie RI. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977;296:1495-7.
19. May DG, Arns PA, Richards WO, Porter J, Ryder D, Fleming CM, et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992;51:689-700.
20. Debruyne D, Gram LF, Grollier G, Camsonne R, Agron L, Dao MT, et al. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. Int J Clin Pharmacol Res 1989;9:319-25.
21. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
22. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
23. Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
24. Eichelbaum M, Bertilsson L, Säwe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982;31:184-6.
25. Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA, Wilkinson GR. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 1985;234:662-9.
26. Adedoyin A, Ryder D, Prakash C, Blair IA, Wilkinson GR. Disposition of hexobarbital in "intermediate metabolizers" of mephenytoin [abstract]. Clin Pharmacol Ther 1992;51:134.
27. Kupfer A, Roberts RK, Schenker S, Branch RA. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981;218:193-9.
28. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
29. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-6.
30. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
31. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;62:365-76.
32. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia: WB Saunders; 1964. p. 1-85.
33. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
34. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984;307:121-7.
35. Chan K. Comparison of gas chromatographic and high-performance liquid chromatographic assays for the determination of debrisoquine and its 4-hydroxy metabolite in human fluids. J Chromatogr 1988;425:311-21.
36. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975;55:347-59.
37. Kunin CM, Glazko AJ, Finland M. Persistence of antibiotics in blood of patients with acute renal failure; I: chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest 1959;36:1498-508.
38. Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone metabolism in liver disease. Clin Pharmacol Ther 1995; 58:198-209.
39. Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green. Clin Pharmacol Ther 1976;20:290-9.
40. Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 1975;17:685-91.
41. Mawer J, Miller NE, Turnberg LA. Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol 1972;44:549-60.
42. Robin DW, Lee M, Hasan SS, Wood AJJ. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:630-7.
43. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2 C subfamily. J Pharmacol Exp Ther 1990;252:442-7.
44. Yasumori T, Chen L, Nagata K, Yamazoe Y, Kato R. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther 1993;264:89-94.
45. Heyn H, White RB, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996;24:948-54.
46. Arns PA, Adedoyin A, DiBisceglie AM, Waggoner JG, Hoofnagle JH, Wilkinson GR, et al. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis. Clin Pharmacol Ther 1997;62:527-37.
47. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-94.
48. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res Rev 1991;16:65-82.
49. Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley G, et al. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 1994;15:1955-61.
50. Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol 1996;91:149-59.
51. Fenyves D, Gariépy L, Villeneuve JP. Clearance by the liver in cirrhosis; I: relationship between propranolol metabolism in vitro and its extraction by the perfused liver in the rat. Hepatology 1993;17:301-6.
52. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987;39:1-47.